Enrollment was defined as randomization, with participants assigned within each cohort in a 6:2 ratio to receive PG-102 or a placebo
It's about which pharmacokinetic profile matches your research objective, and whether your protocol design supports the practical realities of the route you choose
There's going to be more treatment in the comorbidities of obesity, such as heart disease, fatty liver disease, kidney disease, sleep apnea, and other obesity related conditions from substance use to cancer
Phreesia and Clearwave lead this category
Diabetes UK
Klotho mimetics can theoretically suppress phosphate reabsorption in the kidneys, and if KLOW replicates this effect at high doses, the result is phosphate depletion that manifests as muscle weakness, bone demineralization, and in severe cases, rhabdomyolysis